heart failure Archives - CVIA Journal

Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and coronary artery disease, and is closely associated with the high incidence and mortality of heart failure in people with diabetes.

DCM causes microvascular disease, myocardial metabolic disorder, and myocardial fibrosis, thereby leading to left ventricular remodeling, diastolic and/or systolic dysfunction, and eventually progressing to congestive heart failure.

(more…)

Adipokines Pathogenesis in Heart Failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Many studies have reported that obesity causes heart failure (HF) pathogenesis. The elevated circulating levels of angiopoietin-like protein 2 (ANGPTL2) observed in patients with HF suggest potential links among elevated ANGPTL2 levels, metabolic disturbances, and inflammation. C1q/TNF-related protein 3 and C1q/TNF-related protein 9 are diminished in patients with HF with reduced ejection fraction, in proportion to disease severity, and are associated with elevated morbidity and mortality. (more…)

Inflammation in Heart Failure: Mechanisms and Therapeutic Strategies

Announcing a new article publication for journal. Cardiovascular disease remains a leading cause of death and disability worldwide. Heart failure (HF) is the end stage of various cardiovascular diseases. Despite recent advancements in understanding of HF pathogenesis and treatment, the prognosis of patients with HF remains poor. Inflammation is a key player in the development of HF, and its role in the pathogenesis of HF has been extensively studied. Inflammation is associated with elevated HF risk and adverse prognosis. Targeting cardiac inflammation has been suggested as a promising treatment strategy for HF. However, almost all clinical trials on the anti-inflammatory treatment of HF have not indicated improved clinical outcomes, and some have reported deterioration of the condition, possibly because of limited understanding (more…)

Cardiac Magnetic Resonance Imaging in Heart Failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart failure (HF) is a clinical syndrome with a wide variety of clinical presentations, pathophysiologies, and natural histories. HF is becoming more prevalent globally, thus increasing effects on healthcare systems. Cardiac magnetic resonance (CMR) imaging is a valuable tool for better understanding HF and its prognosis.

The commonly used reference standard of CMR cine imaging provides accurate assessment of chamber size and function. Phase contrast imaging can be used to assess the degree of valvular regurgitation and complex flow patterns. Stress perfusion imaging can detect subtle areas of ischemia and microvascular dysfunction.

(more…)

Heart Failure Registries in Asia – What Have We Learned?

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Heart Failure (HF) is one of the leading problems in cardiology practice today. Acute decompensated heart failure (ADHF) is a significant cause of mortality and morbidity worldwide, and this is more relevant in the Asian subcontinent with a high population burden.

Various regional registries in Asia have given us valuable insight into the aetiology and outcomes in this context. Though there are regional differences, it is clear from the review carried out in this paper that HF affects a much younger population.

(more…)

Overview of Injectable Hydrogels for the Treatment of Myocardial Infarction

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Myocardial infarction (MI) triggers adverse remodeling mechanisms, thus leading to heart failure. Since the application of biomaterial-based scaffolds emerged as a viable approach for providing mechanical support and promoting cell growth, (more…)

Transcatheter Aortic Valve Replacement in Patients ≥80 and <80 Years of Age with Aortic Valve Stenosis at Moderate Surgical Risk: Findings from an Observational Study in the Vietnamese Population

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The increasing number of elderly patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement (TAVR) has prompted concerns regarding their clinical outcomes compared with the younger population. This study evaluated the outcomes of TAVR on the basis (more…)

The Development of Ventricular Assist Devices over the Past 30 Years: A Bibliometric Analysis

Announcing a new article publication for Cardiovascular Innovations and Applications journal.

A large gap exists between the needs of patients with end-stage heart failure and the number of gold-standard heart transplants. Over the past 30 years, a revolutionary treatment strategy using ventricular assist devices (VADs) has rapidly developed and become widely used in clinical practice. However, few analyses have assessed the application and publication trends in the VAD field.

The authors of this article used the Web of Science core collection to identify VAD research published between 1992 and 2022. Analysis and data visualization was performed with CiteSpace, Scimago Graphica, and VOSviewer.

13,274 articles published in 1129 journals were identified, describing work from 6351 institutions in 86 countries. Among them, the United States contributed the most to VAD research, and almost all the top ten authors and institutions contributing to VAD research were from the United States.

In the past 5 years, VAD research has focused on right heart failure, outcomes, effects and risk factors, societies of surgeons, and clinical guidelines. Because of the large number of patients with heart failure, it is expected that VAD development to peak in the next decade.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0088

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Zhou Liu, Siyue Zheng and Yazhe Zhang et al. The Development of Ventricular Assist Devices over the Past 30 Years: A Bibliometric Analysis. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0088

Associations of Heart Failure Onset Age with All-Cause Mortality: The Kailuan Study

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at investigating the correlations between heart failure onset age and all-cause mortality.

The study examined 186,249 patients treated at Kailuan Group hospitals who underwent medical evaluations between 2006 and 2018. Biennial health assessments were conducted, and, as of December 31, 2020, 4022 heart failure instances were identified. For each patient with new-onset heart failure, four control participants were randomly selected, matched for age (within ±1 year) and sex. Cox regression models were used to calculate the hazard ratios of all-cause mortality across age groups.

The median follow-up duration was 5.25 (2.65, 8.63) years. All-cause mortality occurred in 1783 participants in the new-onset heart failure group and 2633 participants in in the control group. Refined multivariable Cox regression analysis revealed that patients with heart failure under 55 years of age had the highest relative mortality risk, with an HR (95% CI) 6.86 (4.42–10.64) with respect to their matched controls. Moreover, the relative mortality risk systematically decreased with increasing age of heart failure onset: HR (95% CI) 4.70 (3.73–5.92) for ages 55–64, HR (95% CI) 3.23 (3.73–3.81) for ages 65–74, and HR (95% CI) 1.69 (1.48–1.94) for 75 years or older.

Heart failure significantly elevates the risk of all-cause mortality, and the risk is more pronounced with earlier manifestation of the condition.

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Wei Li, Haibo Gao and Xuemei Zhao et al. Associations of Heart Failure Onset Age with All-Cause Mortality: The Kailuan Study. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0085

Heart Failure Guideline Directed Medical Therapy: Which One and When?

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Over the past several decades, major strides have been made in the management of heart failure with reduced ejection fraction (HFrEF). The 2022 AHA/ACC/HFSA guidelines recommend four drug classes in all patients with symptomatic HFrEF. This guideline directed therapy (GDMT) includes renin angiotensin receptor (RAAS) blockade, preferentially with angiotensin receptor neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter inhibitors (SGLT2i). An optimal GDMT regimen has been estimated to achieve greater than 70% mortality benefit. Unfortunately, most patients with HFrEF are not taking the appropriate medications or doses. Several clinical challenges and questions arise when attempting to initiate and titrate these medications. Although the guidelines offer several suggestions for this process, each patient’s hemodynamic profile varies markedly, thus making development of a uniform algorithm difficult. As new trials are performed, greater emphasis is being placed on more aggressive titration of GDMT. Most importantly, initiation of GDMT should start during hospitalization and continue with close outpatient follow-up. Identifying each patient profile, defined by volume status, blood pressure, heart rate, and kidney function, dictates the order and timing of GDMT titration.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0077

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Michelle Dimza and Juan M. Aranda. Heart Failure Guideline Directed Medical Therapy: Which One and When?. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0077

Tag: heart failure